Recent Updates
Recently added Catalysts
ARGX

argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings

Friday, September 18, 2020 1 min read
Key Takeaway: argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings

Full Press Release Details

argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings.
Tags: ARGX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 18, 2020